Inovio Pharmaceuticals, Inc.

YES - There is still time catch the Mosta-move coming to Inovio

350
As an update to my last chart on Inovio, (Which failed to reach the price targets within he time-frame suggested), I still am witness to extremely Bullish signals. Patience is certainly a key when investing in micro-cap bio-tech stocks.

Inovio maintains a robust pipeline, recently initiated a phase 1 DNA immunotherapy trial for breast, lung and pancreatic cancers, is actively seeking partnership(s) for their ongoing trials and will be presenting detailed analysis of their recently completed phase 2 cervical dysplasia trial in the near future.

My current chart (I believe) shows that "the market" has gained much interest and is awaiting the many possible catalysts that will develop over the next several months.

6 month price target - $12.40 -- 12 month price target $21.00

면책사항

해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.